Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio announced strong progress in 2026, with telitacicept receiving additional commercial approvals in China for autoimmune diseases and ongoing enrollment in global Phase 3 trials for generalized myasthenia gravis and primary Sjögren’s disease. The company reported a pro-forma cash balance of $514.5 million, supporting operations into early 202…